improved hbsag loss to 29.61% by pegintf+nucs 120weeks
Aims: To investigate the improved HBsAgresponse in chronic hepatitis B (CHB) patients treated with prolonged peginterferon α-2a combined with nucleos(t)ide analogue.
Methods: One hundred and fifty-two CHB patients treated with peginterferon α-2a plus nucleos(t)ide analogue from Jan 2007 to Sep 2012 were retrospectively investigated. The mean treatment duration was 79 weeks (range 24-120 weeks). Serum HBsAglevels at baseline, week 12, 24, 36, 48, 72, 96 and 120 of treatment were detected
Results: The cumulative HBsAgloss rates of patients treated at 48-week, 96-week and 120-week with peginterferon α-2a plus nucleos(t)ide analogue were 8.55% (13/152), 26.97% (41/152) and 29.61% (45/152), respectively. The time to HBsAgloss was 74.93±27.21 weeks. Most HBsAgloss occurred during week 49-96. The HBsAglevel at week 12 of treatment in 45 patients who obtained HBsAgloss was 1.91±1.27log10IU/mL, which was significantly lower than baseline (3.22±0.82log10IU/mL) (t=5.759, P< 0.01). However, the HBsAglevel at baseline in 107 patients who did not obtain HBsAgloss was 3.57±0.96 log10 IU/mL and HBsAglevels reduction at week 12, 24, 48, 96 and 120 were 0.24±0.38, 0.45±0.60, 0.83±0.84, 1.29±1.05 and 1.66±1.66 log10IU/ml, respectively (Figure 1). As expected, the HBsAglevel at week 12 of treatment was not significantly different from that at baseline in this group of patients (t=1.529, P=0.128), while that at week 96 was significantly decreased compared with week 48 (t=2.166, P=0.033).
Conclusion: Prolonged peginterferon α-2a combined with nucleos(t)ide analogue treatment could increase the cumulative HBsAgloss rate. In patients who do not obtain HBsAgloss, prolonged therapy could reduce the HBsAglevel and improve the anti-viral response. The reduction of HBsAglevel of week 12 from baseline could be a predictor of HBsAgclearance
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.